PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges

QR Code

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges

Hypercholesterolemia, is a prominent risk factor for cardiovascular disease (CVD). Undestanding of the biochemical mechanisms that regulate the expression of the low density lipoproteins receptor (LDLR) and the hepatic clearance of LDL cholesterol (LDL-C) paved the way to the statin therapy as the g...

Full description

Bibliographic Details
Main Authors:	Norata, Giuseppe, Tibolla, G., Catapano, A.
Format:	Journal Article
Published:	2014
Online Access:	http://hdl.handle.net/20.500.11937/55532

Similar Items

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

PCSK9 inhibitors and dyslipidemia: The clinical evidence
by: Norata, Giuseppe
Published: (2014)

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
by: Baragetti, A., et al.
Published: (2018)

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
by: Baragetti, A., et al.
Published: (2017)

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
by: Grigore, L., et al.
Published: (2013)

New therapeutic principles for familial hypercholesterolemia
by: Norata, Giuseppe
Published: (2014)

Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
by: Watts, G., et al.
Published: (2018)

Challenges in the health economics of familial hypercholesterolemia
by: Norman, Richard, et al.
Published: (2016)

Statins and skeletal muscles toxicity: From clinical trials to everyday practice
by: Norata, Giuseppe, et al.
Published: (2014)

Gene silencing approaches for the management of dyslipidaemia
by: Norata, Giuseppe, et al.
Published: (2013)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

In vivo and in vitro effects of phaleria macrocarpa (scheff.) boerl on low density lipoprotein and pcsk9 expression
by: Chong, Soo Ching
Published: (2011)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

PCSK9 inhibitory activity of marine-derived compounds, aaptaminoids, and benzamide originated from Aaptos aaptos and Acanthaster planci as a potential treatment for atherosclerosis.
by: Habsah, Mohamad, et al.
Published: (2020)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
by: Chong, Soo Ching, et al.
Published: (2011)

Novel compound for use as medicament for treatment of hypercholesterolemia and atherosclerosis
by: Abd. Shukor, Mohd. Yunus, et al.
Published: (2014)

Amaranthus viridis L. as alternative treatment for hypercholesterolemia and atherosclerosis
by: Salvamani, Shamala
Published: (2016)

Patients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment
by: Hardcastle, Sarah, et al.
Published: (2015)

Association Of Single Nucleotide Polymorphisms (Snp) In Pcsk9 Gene With Lipid Analysis Among Iban And Bidayuh Ethnic Groups In Sarawak Population.
by: H. H., Hood, et al.
Published: (2015)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

Functional food mixtures: inhibition of lipid peroxidation, HMGCoA reductase, and ACAT2 in hypercholesterolemia‐induced rats
by: Mohd Rosmi, Noor Syafiqa Aqila, et al.
Published: (2021)

Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
by: Hagger, Martin, et al.
Published: (2018)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease
by: de Gonzalo-Calvo, D., et al.
Published: (2017)

Probiotics as a Promising Treatment for Inflammatory Bowel Disease
by: Mikov, Momir, et al.
Published: (2014)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Novel concepts in HDL pharmacology
by: Remaley, A., et al.
Published: (2014)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

Cannot write session to /tmp/vufind_sessions/sess_n23734t31ae2f0d5r43u004a3s